Ownership at Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) have moved within the range of $9.30 to $18.75. Leerink Swann also issued estimates for Sucampo Pharmaceuticals' FY2019 earnings at $1.79 EPS, FY2020 earnings at $2.02 EPS and FY2021 earnings at $2.19 EPS. Institutional investors and hedge funds own 65.29% of the company's stock. Trexquant Investment LP bought a new stake in Sucampo Pharmaceuticals in the third quarter valued at about $122,000. (NASDAQ:SCMP) established that the company was able to keep return on investment at -40.58 in the trailing twelve month while Reuters data showed that industry's average stands at -12.54 and sector's optimum level is 14.45. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has declined 5.30% since January 12, 2017 and is downtrending. SCMP has diverse figures for different time frames; starting from week's performance it going forward toward positive percentage of 3.06% in last five regular trading sessions. LSV Asset Management grew its holdings in shares of Sucampo Pharmaceuticals by 1.9% in the 2nd quarter. Following the sale, the chief financial officer now owns 348 shares in the company, valued at approximately $5,421.84. Finally, State Board of Administration of Florida Retirement System raised its position in Sucampo Pharmaceuticals by 33.0% in the 3rd quarter.
Growth isn't very attractive to investors if companies are sacrificing profitability and shareholder returns to achieve that growth.
Additionally, according to the most recent 13F filing from Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Credit Suisse Ag owns 0% invested in Sucampo Pharmaceuticals, Inc. The company has market cap of $847.29 million. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. Under the terms of the proposed transaction Sun Acquisition Co., a subsidiary of Mallinckrodt, will commence a cash tender offer to purchase all of the outstanding shares of Sucampo Pharmaceuticals' common stock for $18.00 per share.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, November 1st. They expect $0.34 earnings per share, up 41.67% or $0.10 from last year's $0.24 per share. According to these analysts, the Low Revenue Estimate for Sucampo Pharmaceuticals, Inc.is 73 Million and the High Revenue Estimate is 77.7 Million. For the past 5 years, the company's revenue has grown -14.7%, while the company's earnings per share has grown -51.2%. During the same period in the previous year, the company posted $0.30 earnings per share. analysts forecast that Sucampo Pharmaceuticals will post 1.12 EPS for the current year.
Several research analysts recently weighed in on SCMP shares. Analysts reported that the Price Target for Sucampo Pharmaceuticals, Inc. might touch $43 high while the Average Price Target and Low price Target is $21.29 and $11 respectively. The rating was downgraded by Maxim Group on Tuesday, December 26 to "Hold".
Sucampo Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of 6.35%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of 59.34%. Finally, B. Riley started coverage on shares of Sucampo Pharmaceuticals in a research report on Tuesday, November 14th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and a consensus target price of $21.58.
In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction dated Thursday, December 7th. To cut down amount of noise on price chart, shares of firm has 20 days moving average price of 6.66% from last close price of 18.55 and act as support or resistance of price limit. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and worldwide copyright and trademark law. The legal version of this story can be accessed at https://stocknewstimes.com/2018/01/10/sucampo-pharmaceuticals-scmp-stock-rating-lowered-by-maxim-group.html.
2017, Sucampo Pharmaceuticals, Inc.
- Largest Wildfire In California History Now Contained After Month Of Work
- Iran threatens to retaliate against new USA sanctions
- Capital One Financial Corp. (NYSE:COF) Director Sells $298380.00 in Stock
- AMC Renews 'The Walking Dead'
- Hexavest Inc. Buys Shares of 118373 Chipotle Mexican Grill, Inc. (CMG)
- Lithia Motors Inc (LAD) Director Sells $620000.00 in Stock
- Tractor Supply (NASDAQ:TSCO) Upgraded to Buy by BidaskClub
- Woman Arrested For Husband's Murder After 'How To Kill Someone' Search
- Eagles QB Foles ready to prove doubters wrong
- Dark Souls Remastered will be released for the Switch on May 25